Pipeline

March 5, 2018

Company	Drug/Device	Medical Condition	Status
MabVax Therapeutics Holdings, Inc.	MVT-1075	Pancreatic, colon and lung cancer	Phase I
BioAtla, LLC	BA3011	Advanced solid tumors including non-small cell lung cancer (NSCLC) castration resistant prostate cancer and pancreatic cancer	Phase I/II trials initiated
Galera Therapeutics, LLC	GC4419	Locally advanced pancreatic cancer (LAPC)	Phase I/II trials initiated
Jazz Pharmaceuticals	Defitelio (defibrotide sodium)	Acute Graft-versus-Host-Disease (aGvHD) in adult and pediatric patients after allogenic hematopoietic stem cell transplant (HSCT)	Phase II trials initiated enrolling 150 subjects in the U.S., Canada and European Union
DBV Technologies	Viaskin Milk	IgE-medicated cow’s milk protein allergy	Phase II trials initiated enrolling 198 subjects
Merrimack Pharmaceuticals, Inc.	MM-121 (seribantumab)	Heregulin-positive, hormone rececptor-positive and HER2-negative post-menopausal metastic breast cancer	Phase II trials initiated
ARCA biopharma	Gencaro (bucindolol hydrochloride)	Atrial fibrillation	Phase IIb trials initiated enrolling 267 subjects from the U.S., Canada and Europe
Nuvelution Pharma, Inc.	AUSTEDO	Tourette syndrome in pediatric patients	Phase II/III trials initiated